Edition:
United Kingdom

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Capital Market

5.86USD
15 Feb 2019
Change (% chg)

$0.69 (+13.35%)
Prev Close
$5.17
Open
$5.16
Day's High
$5.98
Day's Low
$5.14
Volume
236,003
Avg. Vol
51,690
52-wk High
$42.83
52-wk Low
$2.74

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Reports Q4 Loss Per Share $0.03
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.03.CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018.Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $3.8 million versus $2.7 million.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million.Q2 loss per share $0.23.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics promotes Sam Martin as CFO
Friday, 16 Jun 2017 

June 16 (Reuters) - Celldex Therapeutics Inc -:Celldex Therapeutics announces additions to the board of directors and senior management team.Celldex Therapeutics Inc - Sam Martin has been promoted to senior vice president and chief financial officer, effective July 1, 2017.Celldex Therapeutics Inc - Martin will assume responsibilities of Avery Catlin, who is retiring on June 30, 2017.  Full Article

Celldex reports Q1 loss per share $0.28
Tuesday, 9 May 2017 

May 9 (Reuters) - Celldex Therapeutics Inc :Celldex reports first quarter 2017 results.Q1 loss per share $0.28.Q1 revenue $1.5 million versus $1.3 million.Q1 revenue view $923,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Q4 revenue $1.9 million versus $5.5 million
Tuesday, 14 Mar 2017 

Celldex Therapeutics Inc : Celldex provides corporate update and reports full year 2016 results . Q4 loss per share $0.30 . Q4 revenue $1.9 million versus $5.5 million . Q4 revenue view $1.1 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex therapeutics - cash, cash equivalents and marketable securities as of dec 31, 2016 were $189.8 million compared to $203.2 million as of sept 30, 2016 . Celldex therapeutics inc says chip catlin, senior vice president and chief financial officer, shared his intention to retire in june this year . Says sam martin, current vice president of finance will be promoted to cfo role concurrent with chip's departure . Celldex therapeutics inc- increase in qtrly revenue was primarily due to clinical trial collaboration with bristol-myers squibb and increase in grant revenue .Celldex therapeutics- cash,cash equivalents,marketable securities at dec 31,enough to meet estimated working capital,fund planned operations through 2018.  Full Article